Featured Research

from universities, journals, and other organizations

Anorexic girls have increased bone density after physiological estrogen treatment, study finds

Date:
June 4, 2011
Source:
The Endocrine Society
Summary:
Estrogen therapy improves low bone density due to anorexia nervosa in teenage girls with the disease when given as a patch or as a low oral dose that is physiological (close to the form or amount of estrogen the body makes naturally), according to a new study.

Estrogen therapy improves low bone density due to anorexia nervosa in teenage girls with the disease when given as a patch or as a low oral dose that is physiological (close to the form or amount of estrogen the body makes naturally).

These results of a new study are being presented at The Endocrine Society's 93rd Annual Meeting in Boston.

A large proportion of adolescents with this eating disorder have low bone density and therefore are at an increased risk of fractures, said Madhusmita Misra, MD, the study's lead author and an associate professor of pediatrics at Harvard Medical School and Massachusetts General Hospital in Boston. An important cause of this low bone density is low levels of estrogen, a hormone in the body that prevents bone loss.

"Previous studies have shown that giving oral estrogen combined with progesterone as birth control pills is not effective in increasing bone density in girls with anorexia nervosa," Misra said. "However, the impact of giving estrogen in a more natural, or physiological, form has not been previously studied in girls with anorexia nervosa."

This National Institutes of Health-funded study explored, over an 18-month period, the effect of physiological estrogen replacement on bone accrual rates in 110 female patients with anorexia nervosa. These patients and 40 healthy-weight girls as controls were between ages 12 to 18 years, a common time for anorexia nervosa to start and also an important time for building optimal bone mass, Misra said.

Girls with anorexia nervosa were randomly assigned to receive either a placebo (an inactive substance) or one of two types of estrogen based on their bone maturity. The researchers estimated bone maturity (whether growth plates had closed) based on wrist and hand X-rays. Those girls with mature bone received either placebo or a full adult dose of estrogen (100 micrograms of estradiol) given via a skin patch. This transdermal form is a natural form of estrogen, Misra said. Girls receiving estrogen also received cyclic progesterone pills to reduce the risk of endometrial cancer.

Girls with anorexia nervosa whose bones were immature received incremental low doses of oral estrogen, ranging from 3.75 to 11.25 micrograms of estradiol. These low, natural levels mimic estrogen levels seen in early puberty and avoid accelerating fusion of the growth plates, which would otherwise limit height potential, Misra said. Healthy-weight controls received no treatment other than calcium and vitamin D supplements, which all subjects received.

Using dual-energy X-ray absorptiometry (DEXA) bone density scans, the researchers assessed bone mineral density at the lumbar spine (lower back), hip and whole body. Physiological estrogen administration caused a significant increase in bone density at the spine and hip, compared with placebo, as found on DEXA Z-scores, the authors reported. However, Misra said that estrogen did not result in a complete "catch-up" to normal bone density measures. Girls with anorexia nervosa still had lower bone density than healthy-weight controls did.

"In addition to weight gain, physiological estrogen could be a potential therapeutic option for optimizing bone mass in girls with anorexia nervosa," Misra said. "The decision to treat would depend on the individual patient and her fracture risks."


Story Source:

The above story is based on materials provided by The Endocrine Society. Note: Materials may be edited for content and length.


Cite This Page:

The Endocrine Society. "Anorexic girls have increased bone density after physiological estrogen treatment, study finds." ScienceDaily. ScienceDaily, 4 June 2011. <www.sciencedaily.com/releases/2011/06/110604182008.htm>.
The Endocrine Society. (2011, June 4). Anorexic girls have increased bone density after physiological estrogen treatment, study finds. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/06/110604182008.htm
The Endocrine Society. "Anorexic girls have increased bone density after physiological estrogen treatment, study finds." ScienceDaily. www.sciencedaily.com/releases/2011/06/110604182008.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins